Related Experiment Video
Updated: Feb 25, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
Cord blood in a rapidly evolving biotherapies landscape
Jessica M Sun1, Joanne Kurtzberg1
1Marcus Center for Cellular Cures, Duke University, Durham, North Carolina, USA.
None:
Since the identification of hematopoietic stem cells (HSCs) in umbilical cord blood (CB) by Broxmeyer in the 1980s,1 the primary clinical use of CB remains as an unrelated donor source for hematopoietic stem cell transplantation (HSCT). However, the presence of additional progenitor cells and growth factors in CB and cord tissue also makes them readily available sources of cells and biomaterials potentially suitable for use as starting material to manufacture a wide range of evolving biotherapies. CB banks, with their existing infrastructure and readily available inventory of fully characterized CB units, are well-positioned to contribute to the development and implementation of CB and cord-tissue based biotherapies.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Blood Transfusion
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
Regulation of Hematopoietic Stem Cells
Hematopoiesis

